Biotheranostics,
Inc., a pioneer in molecular diagnostics for cancer, and Syapse,
the leader in precision medicine software, announce plans to integrate
data from Biotheranostics’ CancerTYPE ID® and Breast Cancer
IndexSM genomic tests into the Syapse Precision Medicine
Platform. The software-based service is part of Syapse’s Global Partner
Program that aims to leverage strong collaborators toward an integrative
approach to precision medicine.

The collaboration allows for seamless integration of patient-specific
results from Biotheranostics’ proprietary biomarkers that provide
molecular profiles for patients with early stage breast cancer and
metastatic cancer into the Syapse Precision Medicine Platform. The
platform is used by health systems and cancer care networks, providing
decision support to clinicians in the care of cancer patients and
enabling health systems to make precision medicine a routine part of
cancer care. Syapse is deployed at some of the largest and most
prominent healthcare institutions in the nation.

Biotheranostics’ Breast Cancer Index helps oncologists make difficult
decisions about extended endocrine therapy for ER+, early stage breast
cancer patients based on its unique ability to predict the risk of late
disease recurrence and identify which patients are likely to benefit
from continuing adjuvant endocrine therapy beyond five years. Its
CancerTYPE ID is a rigorously validated gene expression-based test for
metastatic patients with diagnostic ambiguity. By providing a molecular
classification of tumor type, results are used in conjunction with
standard clinical and pathological assessment, which may help physicians
determine optimal targeted treatment regimens with the goal of improving
patient outcomes.

“We are excited to work with Syapse to make our Breast Cancer Index and
CancerTYPE ID clinical testing services available to more health systems
through the Syapse Precision Medicine Platform,” said Nicolas
Barthelemy, President and Chief Executive Officer of Biotheranostics.
“Precision medicine promises to transform healthcare over the next
several decades. We are committed to helping physicians find the most
effective treatment for each cancer patient based on his or her specific
molecular profile. Integrating data from our molecular tests with the
Syapse platform will better help physicians harness individualized
patient information to extend lives and reduce costs.”

About Syapse

Syapse drives healthcare transformation through precision medicine,
enabling provider systems to improve clinical outcomes, streamline
operations, and shift to new payment models. Syapse Precision Medicine
Platform is a comprehensive software suite used by leading health
systems to support the clinical implementation of precision medicine in
oncology and other service lines. This category-defining platform
enables clinical and genomic data integration, decision support, care
coordination, and quality improvement at point of care. Headquartered in
Palo Alto, California, with offices in Philadelphia, Pennsylvania,
Syapse is backed by Ascension Ventures, Safeguard Scientifics
(NYSE:SFE), and Social Capital. For more information, visit syapse.com.

About Biotheranostics

Biotheranostics, Inc., is a leader in helping physicians improve the
care of cancer patients, offering a suite of proprietary genomics-based
molecular diagnostics that allow treatment to be tailored to individual
patients. The company’s Breast
Cancer IndexSM and CancerTYPE
ID® tests address a variety of unmet medical needs in the
management of cancer patients, and extensive clinical studies have
confirmed the accuracy, clinical validity, clinical utility, and
cost-effectiveness of the tests. Biotheranostics operates a
CLIA-certified, CAP-accredited diagnostic laboratory in San Diego. Learn
more at biotheranostics.com.

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her
physician.